Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
90 participants
Oct 24, 2024
INTERVENTIONAL
Conditions
Summary
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Eligibility
Inclusion Criteria4
- Fully understand the study and voluntarily sign the informed consent form.
- -75 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；
- Life expectancy ≥ 12 weeks.
Exclusion Criteria1
- Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
10 mg/kg or 20 mg/kg administered intravenously Q3w
15 mg/kg administered intravenously Q3w
200 mg administered intravenously Q3w
15 mg/kg administered intravenously Q3w
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06558227